Aipo Diao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aipo Diao has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
Yuyin Li
School of Biotechnology, Tianjin University of Science and Technology, Tianjin, China
26 shared publicationsZhenxing Liu
School of Biotechnology, Tianjin University of Science and Technology, Tianjin 300457, China
14 shared publications- Yuyin Li
State Key Laboratory of Food Nutrition and Safety, Tianjin University of Science and Technology, Tianjin China
11 shared publications Lei Jing
Key Lab of Industrial Fermentation Microbiology of the Ministry of Education School of Biotechnology, Tianjin University of Science and Technology Tianjin China
10 shared publicationsJieru Lin
College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China
8 shared publicationsQing Zhao
School of Biotechnology, Tianjin University of Science and Technology, Tianjin, China
8 shared publications
Latest Publications
- 23 September 2025
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 189, 106865
Escin alleviates DNCB-induced atopic dermatitis-like symptoms by promoting autophagy activation and tight junction barrier restoration
- 23 September 2025
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 189, 106865
Escin alleviates DNCB-induced atopic dermatitis-like symptoms by promoting autophagy activation and tight junction barrier restoration
- 5 December 2024
- Published by Elsevier in Biochemical Pharmacology
- Vol. 232, 116694
The TFEB activator clomiphene citrate ameliorates lipid metabolic syndrome pathology by activating lipophagy and lipolysis
- 5 December 2024
- Published by Elsevier in Biochemical Pharmacology
- Vol. 232, 116694
The TFEB activator clomiphene citrate ameliorates lipid metabolic syndrome pathology by activating lipophagy and lipolysis
- Open Access
- 23 October 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (12) , 107929
TFEB agonist clomiphene citrate activates the autophagy-lysosomal pathway and ameliorates Alzheimer's disease symptoms in mice
- 23 October 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (12) , 107929
Open AccessTFEB agonist clomiphene citrate activates the autophagy-lysosomal pathway and ameliorates Alzheimer's disease symptoms in mice
- Open Access
- 18 September 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1449178
The novel TFEB agonist desloratadine ameliorates hepatic steatosis by activating the autophagy-lysosome pathway
The autophagy-lysosome pathway plays an essential role in promoting lipid catabolism and preventing hepatic steatosis in non-alcoholic fatty liver disease (NAFLD). Transcription factor EB (TFEB) enhances the autophagy-lysosome pathway by regulating the expression of genes related to autophagy and lysosome biogenesis. Therefore, targeting TFEB provides a novel strategy for the treatment of lipid metabolic diseases. In this study, the antiallergic drug desloratadine was screened and identified as a novel TFEB agonist. Desloratadine effectively induced translocation of TFEB to the nucleus and promoted autophagy and lysosome biogenesis. Desloratadine-induced TFEB activation was dependent on AMPK rather than mTORC1. Moreover, desloratadine treatment enhanced clearance of lipid droplets in cells induced by fatty acids oleate and palmitate. Furthermore, high-fat diet (HFD) induced obesity mouse model experiments indicated treatment with desloratadine markedly reduced the body weight of HFD-fed mice, as well as the levels of hepatic triglycerides and total cholesterol, serum glutamic pyruvic transaminase and glutamic-oxaloacetic transaminase. Oil red O staining showed the liver fat was significantly reduced after desloratadine treatment, and H&E staining analysis demonstrated hepatocellular ballooning was improved. In addition, autophagy and lysosomal biogenesis was stimulated in the liver of desloratadine treated mice. Altogether, these findings demonstrate desloratadine ameliorates hepatic steatosis through activating the TFEB-mediated autophagy-lysosome pathway, thus desloratadine has an exciting potential to be used to treat fatty liver disease.
- 18 September 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1449178
Open AccessThe novel TFEB agonist desloratadine ameliorates hepatic steatosis by activating the autophagy-lysosome pathway
The autophagy-lysosome pathway plays an essential role in promoting lipid catabolism and preventing hepatic steatosis in non-alcoholic fatty liver disease (NAFLD). Transcription factor EB (TFEB) enhances the autophagy-lysosome pathway by regulating the expression of genes related to autophagy and lysosome biogenesis. Therefore, targeting TFEB provides a novel strategy for the treatment of lipid metabolic diseases. In this study, the antiallergic drug desloratadine was screened and identified as a novel TFEB agonist. Desloratadine effectively induced translocation of TFEB to the nucleus and promoted autophagy and lysosome biogenesis. Desloratadine-induced TFEB activation was dependent on AMPK rather than mTORC1. Moreover, desloratadine treatment enhanced clearance of lipid droplets in cells induced by fatty acids oleate and palmitate. Furthermore, high-fat diet (HFD) induced obesity mouse model experiments indicated treatment with desloratadine markedly reduced the body weight of HFD-fed mice, as well as the levels of hepatic triglycerides and total cholesterol, serum glutamic pyruvic transaminase and glutamic-oxaloacetic transaminase. Oil red O staining showed the liver fat was significantly reduced after desloratadine treatment, and H&E staining analysis demonstrated hepatocellular ballooning was improved. In addition, autophagy and lysosomal biogenesis was stimulated in the liver of desloratadine treated mice. Altogether, these findings demonstrate desloratadine ameliorates hepatic steatosis through activating the TFEB-mediated autophagy-lysosome pathway, thus desloratadine has an exciting potential to be used to treat fatty liver disease.
- 1 March 2023
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 235, 123859
TMEPAI promotes degradation of the NF-κB signaling pathway inhibitory protein IκBα and contributes to tumorigenesis
- 1 March 2023
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 235, 123859
TMEPAI promotes degradation of the NF-κB signaling pathway inhibitory protein IκBα and contributes to tumorigenesis
- 30 September 2022
- Published by Elsevier in European Journal of Pharmacology
- Vol. 934, 175307
The novel prolyl hydroxylase-2 inhibitor caffeic acid upregulates hypoxia inducible factor and protects against hypoxia
- 30 September 2022
- Published by Elsevier in European Journal of Pharmacology
- Vol. 934, 175307
The novel prolyl hydroxylase-2 inhibitor caffeic acid upregulates hypoxia inducible factor and protects against hypoxia
- 19 February 2022
- Published by Elsevier in Protein Expression and Purification
- Vol. 194, 106073
Production of functional recombinant prolyl hydroxylase-2 enzyme in insect cells for small molecule inhibitor screening studies
- 19 February 2022
- Published by Elsevier in Protein Expression and Purification
- Vol. 194, 106073
Production of functional recombinant prolyl hydroxylase-2 enzyme in insect cells for small molecule inhibitor screening studies
- 1 October 2021
- Published by Canadian Science Publishing in Biochemistry and Cell Biology
- Vol. 99 (5) , 519-526
Cetrimonium bromide promotes the clearance of lipids by activating the TFEB-mediated autophagosome–lysosome pathway in hepatic cells
Autophagy plays a key role in the metabolism of macromolecules via the degradative abilities of the lysosome. Transcription factor EB (TFEB) regulates autophagosome biogenesis and lysosome function, and promoting TFEB activity has emerged as a potential strategy for the treatment of metabolic disorders. Herein, we report that cetrimonium bromide (CTAB; a quaternary ammonium compound) promotes autophagy and lysosomal biogenesis by inducing the nuclear translocation of TFEB in hepatic cells. Knockdown of TFEB mediated by short hairpin RNA inhibits CTAB-induced autophagy and lysosomal biogenesis. Mechanistically, CTAB treatment inhibits the Akt–mTORC1 signaling pathway. Moreover, CTAB treatment significantly increases lipid metabolism in both palmitate- and oleate-treated HepG2 cells, and this increase was attenuated by knockdown of TFEB. Collectively, our results indicate that CTAB activates the autophagosome–lysosome pathway via inducing the nuclear translocation of TFEB by inhibiting the mTORC1 signaling pathway. These results add to the collective understanding of TFEB function and provide new insights into CTAB-mediated lipid metabolism.
- 1 October 2021
- Published by Canadian Science Publishing in Biochemistry and Cell Biology
- Vol. 99 (5) , 519-526
Cetrimonium bromide promotes the clearance of lipids by activating the TFEB-mediated autophagosome–lysosome pathway in hepatic cells
Autophagy plays a key role in the metabolism of macromolecules via the degradative abilities of the lysosome. Transcription factor EB (TFEB) regulates autophagosome biogenesis and lysosome function, and promoting TFEB activity has emerged as a potential strategy for the treatment of metabolic disorders. Herein, we report that cetrimonium bromide (CTAB; a quaternary ammonium compound) promotes autophagy and lysosomal biogenesis by inducing the nuclear translocation of TFEB in hepatic cells. Knockdown of TFEB mediated by short hairpin RNA inhibits CTAB-induced autophagy and lysosomal biogenesis. Mechanistically, CTAB treatment inhibits the Akt–mTORC1 signaling pathway. Moreover, CTAB treatment significantly increases lipid metabolism in both palmitate- and oleate-treated HepG2 cells, and this increase was attenuated by knockdown of TFEB. Collectively, our results indicate that CTAB activates the autophagosome–lysosome pathway via inducing the nuclear translocation of TFEB by inhibiting the mTORC1 signaling pathway. These results add to the collective understanding of TFEB function and provide new insights into CTAB-mediated lipid metabolism.
- 24 September 2021
- Published by Wiley in Phytotherapy Research
- Vol. 35 (11) , 6441-6451
Quercetin inhibiting the PD‐1/PD‐L1 interaction for immune‐enhancing cancer chemopreventive agent
Targeting the PD‐1/PD‐L1 immune checkpoints has achieved significant positive results in the treatment of multiple cancers. Quercetin is one of the most abundant dietary flavonoids found in various vegetables and fruits, and has a wide range of biological activities including immunomodulation. Here we report that quercetin dihydrate was screened and shown to inhibit the PD‐1/PD‐L1 interaction. Treatment with quercetin dihydrate promoted the killing activity of T cells on MDA‐MB‐231 and NCI‐H460 cancer cells. Experiments using the xenograft mouse model showed that the growth rate of tumor volumes and masses in the quercetin dihydrate‐treated mice were decreased. Immunohistochemistry of the tumors showed that CD8, GZMB, and IFN‐γ were increased in the quercetin dihydrate‐treated mice. These results suggest that quercetin dihydrate attenuates the inhibitory effect of PD‐L1 on T cells by inhibiting the PD‐1/PD‐L1 interaction, which has an exciting potential to be used as a cancer chemopreventive agent.
- 24 September 2021
- Published by Wiley in Phytotherapy Research
- Vol. 35 (11) , 6441-6451
Quercetin inhibiting the PD‐1/PD‐L1 interaction for immune‐enhancing cancer chemopreventive agent
Targeting the PD‐1/PD‐L1 immune checkpoints has achieved significant positive results in the treatment of multiple cancers. Quercetin is one of the most abundant dietary flavonoids found in various vegetables and fruits, and has a wide range of biological activities including immunomodulation. Here we report that quercetin dihydrate was screened and shown to inhibit the PD‐1/PD‐L1 interaction. Treatment with quercetin dihydrate promoted the killing activity of T cells on MDA‐MB‐231 and NCI‐H460 cancer cells. Experiments using the xenograft mouse model showed that the growth rate of tumor volumes and masses in the quercetin dihydrate‐treated mice were decreased. Immunohistochemistry of the tumors showed that CD8, GZMB, and IFN‐γ were increased in the quercetin dihydrate‐treated mice. These results suggest that quercetin dihydrate attenuates the inhibitory effect of PD‐L1 on T cells by inhibiting the PD‐1/PD‐L1 interaction, which has an exciting potential to be used as a cancer chemopreventive agent.